A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors

NCT07253116 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: WJ22096

Sponsor

Nanjing Jingao biomidical technology Co. Ltd.